123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE)
Gabriel Rinnerthaler(Medical University of Graz), Richard Greil(Paracelsus Medical University), Ursula Denison(Karl Landsteiner Society), Christian F. Singer(Comprehensive Cancer Center Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Michael Knauer(Breast Center), Vesna Bjelic‐Radisic(Helios Universitätsklinikum Wuppertal), Andreas Petzer(Ordensklinikum Linz Barmherzige Schwestern), Martin Filipits(University of Vienna), Lidija Sölkner(Austrian Breast & Colorectal Cancer Study Group), Simon Peter Gampenrieder(University of Salzburg), Clemens A. Schmitt(Kepler Universitätsklinikum), Rupert Bartsch(Universitätszahnklinik Wien), Daniel Egle(Innsbruck Medical University), Marija Balić(University of Pittsburgh), Edgar Petru(Medical University of Graz), M.I. Gnant(Comprehensive Cancer Center Vienna), Florian Posch(Medical University of Graz), Manuela Gili(Austrian Breast & Colorectal Cancer Study Group), Dominik Hlauschek(Austrian Breast & Colorectal Cancer Study Group)
Cited by 2
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Senescence and cancer — role and therapeutic opportunities
|Nature Reviews Clinical Oncology|2022|727
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Inferring expressed genes by whole-genome sequencing of plasma DNA
|Nature Genetics|2016|463